Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer
作者： Ruth Whittington , Diana Faulds
DOI: 10.2165/00003495-199346030-00009
关键词:
摘要: Synopsis Recombinant interleukin-2 (IL-2) products (eg aldesleukin, teceleukin) are nonglycosylated, modified forms of the endogenous compound. IL-2 acts as a pleiotropic mediator …
springer.com
sci-hub.se 参考文章(523)
Jean-Marc Tourani, Vincent Levy, Josette Briere, Rafaël Levy, Chris Franks, Jean-Marie Andrieu, Interleukin-2 therapy for refractory and relapsing lymphomas. European Journal of Cancer and Clinical Oncology. ,vol. 27, pp. 1676- 1680 ,(1991) , 10.1016/0277-5379(91)90444-I
Julio Benitez, JoséM Ladero, Carlos Jara, Juan A Carrillo, Jesús Cobaleda, Adrián Llerena, Emilio Vargas, Juan J Muñoz, None, Polymorphic oxidation of debrisoquine in lung cancer patients European Journal of Cancer and Clinical Oncology. ,vol. 27, pp. 158- 161 ,(1991) , 10.1016/0277-5379(91)90477-U
Christopher J. Verdi, Charles W. Taylor, Marilyn K. Croghan, Patricia Dalke, Frank L. Meyskens, Evan M. Hersh, Phase I study of low-dose cyclophosphamide and recombinant interleukin-2 for the treatment of advanced cancer. Journal of Immunotherapy. ,vol. 11, pp. 286- 291 ,(1992) , 10.1097/00002371-199205000-00007
Jean-Marie J. Heslan, Anne I. Branellec, Philippe Lang, Gilbert Lagrue, Recombinant interleukin-2-induced proteinuria: fact or artifact? Nephron. ,vol. 57, pp. 373- 374 ,(1991) , 10.1159/000186293
Joseph A. Sparano, Janice P. Dutcher, Ronald Kaleya, Geralyn Caliendo, Joseph Fiorito, Sumi Mitsudo, Richard Shechner, Scott J. Boley, Rasim Gucalp, Niculae Ciobanu, Kathleen Grima, Peter H. Wiernik, Lawrence J. Brandt, Colonic ischemia complicating immunotherapy with interleukin‐2 and interferon‐alpha Cancer. ,vol. 68, pp. 1538- 1544 ,(1991) , 10.1002/1097-0142(19911001)68:7<1538::AID-CNCR2820680714>3.0.CO;2-2
Deric D. Schoof, Yasunori Terashima, Steven Batter, Linda Douville, Jerome P. Richie, Timothy J. Eberlein, Survival characteristics of metastatic renal cell carcinoma patients treated with lymphokine-activated killer cells plus interleukin-2 Urology. ,vol. 41, pp. 534- 539 ,(1993) , 10.1016/0090-4295(93)90100-O
D. Diana, J. P. Sculier, Haemodynamic effects induced by intravenous administration of high doses of r-Met Hu IL-2 [ala-125] in patients with advanced cancer. Intensive Care Medicine. ,vol. 16, pp. 167- 170 ,(1990) , 10.1007/BF01724796
R. Nora, J. S. Abrams, N. S. Tait, D. J. Hiponia, H. J. Silverman, Myocardial Toxic Effects During Recombinant Interleukin-2 Therapy Journal of the National Cancer Institute. ,vol. 81, pp. 59- 63 ,(1989) , 10.1093/JNCI/81.1.59
Paolo Alberto Paciucci, James F. Holland, James S. Ryder, Robert G. Konefal, George J. Bekesi, Rosalie Odchimar, Ronald Gordon, Immunotherapy with interleukin-2 by constant infusion with and without adoptive cell transfer and with weekly doxorubicin Cancer Treatment Reviews. ,vol. 16, pp. 67- 81 ,(1989) , 10.1016/0305-7372(89)90026-1
RICHARD WELBOURN, GIDEON GOLDMAN, LESTER KOBZIK, C. R. VALERI, DAVID SHEPRO, HERBERT B. HECHTMAN, Involvement of thromboxane and neutrophils in multiple-system organ edema with interleukin-2. Annals of Surgery. ,vol. 212, pp. 728- 733 ,(1990) , 10.1097/00000658-199012000-00012